[1]陈美岑,等.柔肝化纤颗粒对失代偿期肝硬化患者肠道菌群的影响[J].西部中医药,2021,34(12):99-101.[doi:10.12174/j.issn.2096-9600.2021.12.26]
　CHEN Meicen,WANG Zhenchang,et al.Effects of Rougan Huaxian Granules on Intestinal Flora in Patients with Decompensated Cirrhosis[J].Western Journal of Traditional Chinese Medicine,2021,34(12):99-101.[doi:10.12174/j.issn.2096-9600.2021.12.26]
点击复制

柔肝化纤颗粒对失代偿期肝硬化患者肠道菌群的影响
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
34
期数:
2021年12期
页码:
99-101
栏目:
出版日期:
2021-12-15

文章信息/Info

Title:
Effects of Rougan Huaxian Granules on Intestinal Flora in Patients with Decompensated Cirrhosis
作者:
陈美岑,, 王振常,
1.广西中医药大学，广西 南宁 530001
2.广西中医药大学附属国际壮医医院
Author(s):
CHEN Meicen,, WANG Zhenchang,
1.Guangxi University of Chinese Medicine, Nanning 530001, China
2.Guangxi International Zhuang Medicine Hospital Affiliated to Guangxi University of Chinese Medicine
关键词:
肝硬化; 失代偿期; 肠道菌群失衡; 柔肝化纤颗粒; 临床研究
Keywords:
decompensated cirrhosis; the imbalance of intestinal flora; granules; clinical study
分类号:
R657.3+1
DOI:
10.12174/j.issn.2096-9600.2021.12.26
文献标志码:
B
摘要:
目的研究柔肝化纤颗粒对失代偿期肝硬化患者肠道菌群的影响。 方法选取66例肝硬化失代偿期肠道菌群失衡患者，随机分为观察组和对照组，每组33例。对照组予常规西医治疗，观察组在常规西医治疗的基础上服用柔肝化纤颗粒，比较两组肝功能指标及肠道菌群变化情况。 结果治疗后，两组谷氨酸氨基转移酶（alanine aminotransferase，ALT）、天冬氨酸氨基转移酶（aspartate aminotransferase，AST）、总胆红素（total bilirubin，TBIL）较治疗前明显降低，差异有统计学意义（P＜0.05），且观察组肝功能改善情况优于对照组（P＜0.05）。观察组双歧杆菌、乳杆菌较治疗前增高，大便肠球菌、酵母菌较治疗前降低，差异均有统计学意义（P＜0.05），对照组肠道菌群各指标改善不明显，差异无统计学意义（P＞0.05）；观察组肠道菌群指标改善情况优于对照组（P＜0.05）。 结论柔肝化纤颗粒能够有效改善肝硬化失代偿期患者肠道菌群失衡状态及肝功能，其治疗肝硬化的机制之一可能与调控肠道菌群有关。
Abstract:
ObjectiveTo study the effects of Rougan Huaxian granules on intestinal flora in patients with decompensated cirrhosis. MethodsAll 66 patients with decompensated cirrhosis and the imbalance of intestinal flora were chosen and randomly allocated to the observation group and the control group, 33 cases in each group. The control group accepted conventional Western medicine, and the observation group took Rougan Huaxian granules based on conventional Western medicine, to compare the indexes of liver function and the changes of intestinal flora between both groups. ResultsAfter treating, the levels of ALT, AST and TBIL of both groups lowered significantly than before the treatment, and the difference had statistical meaning (P<0.05), and the improvements of liver function of the observation group were better than these of the control group (P<0.05).Bifidobacterium and lactobacillus were higher than those before treatment, enterococcus faecalis and yeast were lower than those before treatment in the observation group, and the difference had statistical meaning (P<0.05), the improvements of the indexes of intestinal flora in the control group were insignificant, and the difference had no statistical meaning (P>0.05); the improvements of the indexes of intestinal flora of the observation group were better than these of the control group (P<0.05). ConclusionRougan Huaxian granules could effectively improve intestinal flora and liver function in patients with decompensated cirrhosis, and one of the mechanism of treating liver cirrhosis might be related to regulating intestinal flora.

相似文献/References:

[1]樊红,冯彦虎,张德奎△,等.中西医结合治疗肝炎后肝硬化腹水疗效观察[J].西部中医药,2013,26(02):91.
　FAN Hong,FENG Yanhu,ZHANG Dekui,et al.Clinical Observation on Integrative Medicine in Treating Cirrhosis Ascites of Patients with Hepatitis[J].Western Journal of Traditional Chinese Medicine,2013,26(12):91.
[2]刘建军,曾贤翠,郝淑萍,等.腹水超滤浓缩回输联合中医辨证治疗肝硬化顽固性腹水40例临床观察[J].西部中医药,2013,26(06):1.
　LIUJianjun,ZENGXiancui,HAOShuping,et al.ClinicalObservationonUltrafiltrationReinfusionofConcentratedAscitesandSyndromeDifferentiationforRefractoryAscitesofLiverCirrhosis:AReportof40Cases[J].Western Journal of Traditional Chinese Medicine,2013,26(12):1.
[3]张萍,朱建坤.肝硬化患者应用中医食疗的临床护理分析[J].西部中医药,2013,26(07):112.
　ZHANG Ping,ZHU Jiankun.Analysis on Clinical Nursing for Liver Cirrhosis Patients Given with TCM Food Therapy[J].Western Journal of Traditional Chinese Medicine,2013,26(12):112.
[4]闫雪华.恩替卡韦联合复方鳖甲软肝片治疗代偿期乙肝肝硬化疗效观察[J].西部中医药,2014,27(07):84.
　YAN Xuehua.Clinical Observation on Entecavir Combined with Compound BieJia RuanGan Tablets in Treating Decompensated Liver Cirrhosis of Hepatitis B[J].Western Journal of Traditional Chinese Medicine,2014,27(12):84.
[5]黄鸿娜,黄晶晶△,王振常,等.柔肝化纤颗粒治疗肝硬化脾功能亢进症的临床观察[J].西部中医药,2014,27(09):111.
[6]龚红霞,邱晶.多层螺旋CT门静脉成像在肝硬化中医证型诊断中的应用价值[J].西部中医药,2018,31(12):147.
　GONG Hongxia,QIU Jing.Application Value of Multilayer Spiral CT Portal Vein Imaging in the Diagnosis of TCM Patterns of Liver Cirrhosis[J].Western Journal of Traditional Chinese Medicine,2018,31(12):147.
[7]朱艳国,朱艳丽△,张金花.自拟化积膏治疗肝硬化疗效观察[J].西部中医药,2019,32(05):63.
　ZHU Yanguo,ZHU Yanli,ZHANG Jinhua.Clinical Observation on Selfmade HuaJi Ointment in Treating Cirrhosis[J].Western Journal of Traditional Chinese Medicine,2019,32(12):63.
[8]徐婷婷,安振涛,李慧,等.肝硬化腹水证治分布及脐敷疗法用药规律文献研究[J].西部中医药,2021,34(06):85.[doi:10.12174/j.issn.2096-9600.2021.06.20]
　XU Tingting,AN Zhentao,LI Hui,et al.Literature Study on the Distribution of Syndrome Differentiation and Treatment of Cirrhosis Ascites and Medication Rules of Umbilical Compressing Therapy[J].Western Journal of Traditional Chinese Medicine,2021,34(12):85.[doi:10.12174/j.issn.2096-9600.2021.06.20]
[9]马玉珍,毛德文,覃艳新,等.六味醒神颗粒治疗肝硬化轻微型肝性脑病的临床疗效及其对血氨和内毒素的影响[J].西部中医药,2021,34(05):7.[doi:10.12174/j.issn.2096-9600.2021.05.03]
　MA Yuzhen,MAO Dewen,QIN Yanxin,et al.Clinical Effects of Liuwei Xingshen Granules in Treating Mild Hepatic Encephalopathy of Liver Cirrhosis and Its Influence on Blood Ammonia and Endotoxin[J].Western Journal of Traditional Chinese Medicine,2021,34(12):7.[doi:10.12174/j.issn.2096-9600.2021.05.03]
[10]吴铁雄,刘旭东,朱沪敏,等.大黄?虫胶囊联合心得安治疗乙肝肝硬化门脉高压症临床观察[J].西部中医药,2023,36(02):102.[doi:10.12174/j.issn.2096-9600.2023.02.23]
　WU Tiexiong,LIU Xudong,ZHU Humin,et al.Clinical Observation on Dahuang Zhechong Capsules and Propranolol in the Treatment of Portal Hypertension of Hepatitis B Cirrhosis[J].Western Journal of Traditional Chinese Medicine,2023,36(12):102.[doi:10.12174/j.issn.2096-9600.2023.02.23]

备注/Memo

备注/Memo:
陈美岑（1992—），女，在读硕士研究生。研究方向：肝纤维化、肝硬化的中西医结合临床研究。国家自然科学基金（81660745）；广西中医药大学2019年研究生教育创新计划项目（XYJ19100）；医疗卫生适宜技术研究与开发项目（S201676）。
更新日期/Last Update: 2021-12-15